Showing that an administered substance reaches a target compartment is not the same as showing that patients benefit. This trial measured both delivery and clinical outcomes. Primary report
Study snapshot
The double-blind trial randomized 153 participants with cystic fibrosis to inhaled glutathione or placebo for six months. Primary lung-function comparisons were not significant. Exacerbations and quality-of-life outcomes did not favor treatment. Sputum measurements supported delivery to the airways, but the report did not demonstrate the expected accompanying changes in oxidative or inflammatory markers. Primary report
Our appraisal: examine each step of the proposed chain
The proposed sequence is delivery, biological action, and clinical improvement. Evidence for the first step cannot be used as evidence for all three. A study can successfully deliver a compound while failing to demonstrate its intended downstream effect.
Time-specific findings also require discipline. An exploratory improvement at an intermediate visit should not replace the prespecified overall comparison. The endpoint schedule and analysis hierarchy determine whether a finding was a planned test or a hypothesis-generating observation.
This distinction helps prevent a common evidence error: explaining away every unsuccessful clinical result by pointing to a favorable biomarker. The biomarker may show exposure, but the clinical question still needs its own answer.
The tested formulation, nebulizer, population, and route remain part of the evidence. These results cannot validate an unrelated oral or injectable product. Full review should inspect adherence, missing measurements, adverse-event definitions, and confidence intervals before describing what degree of benefit was excluded. This record does not provide inhalation instructions or a cystic-fibrosis treatment plan.
Frequently asked questions
Did the study demonstrate airway delivery?
Sputum measurements supported delivery.
Did that establish clinical improvement?
No. The primary clinical comparisons did not demonstrate it.
Did fewer exacerbations support treatment?
The report did not show that advantage.
Can an intermediate-visit result replace the primary analysis?
No.
Is a delivery marker necessarily a marker of therapeutic action?
No. Those are separate questions.
Can this validate other glutathione routes?
Not directly.
What is the key takeaway?
Retain the distinction between reaching the target and improving patient outcomes.